Freshfields advises CVC Capital Partners VIII on its investment in Rayner
Freshfields Bruckhaus Deringer (‘Freshfields’) is advising CVC Capital Partners VIII, part of leading private equity and investment advisory firm CVC, on its majority investment in Rayner, the global ophthalmology business, from Phoenix Equity Partners.
Rayner is a manufacturer and developer of innovative intraocular lenses (IOLs) and associated pharmaceuticals. The Company’s products deliver sight-restorative implants and treatments to patients during cataract and refractive surgeries. Operating from their state-of-the-art headquarters in Worthing, UK, the Company, which developed the world’s first IOL in 1949, now makes these and other products available to patients in over 80 countries, through its subsidiaries and distribution networks, to improve the eyesight of more than 300,000 patients per year.
With CVC’s backing, Rayner will pursue a strategy focused on driving both organic and inorganic growth, while further enhancing Rayner’s established reputation for innovation and product excellence. Benefitting from CVC’s international reach and experience of the healthcare sector, Rayner is poised to continue its growth as a leading global operator as demand for its broad suite of products and services in ophthalmology continues to grow.
The Freshfields team advising on the transaction is led by Charles Hayes and Victoria Sigeti, alongside David Brooks, Gina Bicknell, David Mendel, Jill Gatehouse and Ali Kirby-Harris.
Notes to editors
About Freshfields Bruckhaus Deringer
Freshfields Bruckhaus Deringer LLP is a global law firm with a long track record of successfully advising the world's leading national and multinational corporations and financial institutions on ground-breaking and business-critical challenges. Our team of more than 2,800 lawyers and other legal professionals delivers global results from our 28 offices worldwide. Our commitment, local and multinational expertise and business know-how means our clients can rely on us when it matters most.